It remains plausible that targeting TNF-α may confer benefits in select patient populations, such as those experiencing cancer-related cachexia or chronic inflammatory states, but concerns regarding systemic immune suppression continue to temper enthusiasm for this approach. Here, TNF is linked to cancer.